Clinical trial
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer…
NCT00076856 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00076856 |
|---|---|
| Title | Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247) |
| Official title | A Randomized, Open-Label Phase 2 Study of Temozolomide Added to Whole Brain Radiation Therapy Versus Whole Brain Radiation Therapy Alone for the Treatment of Brain Metastasis From Non-Small Cell Lung Cancer |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Brain Neoplasms |
| Intervention type | Drug |
| Interventions | Temozolomide |
| Enrollment | 95 |
| Start date | Mar 31, 2004 |
| Primary completion | Mar 31, 2006 |
| Completion | Mar 31, 2006 |
| First posted | Feb 6, 2004 |
| Last update posted | May 9, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: